Neurogene Inc. $NGNE Shares Bought by Renaissance Technologies LLC

Renaissance Technologies LLC boosted its holdings in Neurogene Inc. (NASDAQ:NGNE) by 210.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 43,400 shares of the company’s stock after purchasing an additional 29,400 shares during the quarter. Renaissance Technologies LLC owned about 0.27% of Neurogene worth $875,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the company. BNP Paribas Financial Markets grew its stake in Neurogene by 89.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock valued at $36,000 after acquiring an additional 978 shares during the last quarter. Daiwa Securities Group Inc. purchased a new stake in Neurogene in the fourth quarter valued at approximately $66,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Neurogene by 17.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after buying an additional 1,059 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Neurogene in the 4th quarter valued at about $165,000. Finally, Bridgeway Capital Management LLC purchased a new stake in shares of Neurogene during the 3rd quarter valued at about $187,000. Hedge funds and other institutional investors own 52.37% of the company’s stock.

Neurogene News Summary

Here are the key news stories impacting Neurogene this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $65 price target while raising its FY2027 EPS forecast to a loss of $4.99 per share from a projected loss of $5.92. The firm also lifted its estimates for the first three quarters of 2027, indicating expectations for reduced losses over time.
• Positive Sentiment: HC Wainwright increased its Q4 2026 EPS estimate to a loss of $1.20 from $1.37 and raised its Q1–Q4 2027 estimates to losses of $1.22, $1.24, $1.26 and $1.27, respectively. These revisions suggest improving operating expectations beyond 2026.
• Positive Sentiment: Canaccord Genuity lowered its price target to $166, but the revised target remains substantially above Neurogene’s recent trading level, potentially reinforcing the stock’s significant upside narrative. Canaccord Genuity Group Lowers Neurogene Price Target
• Neutral Sentiment: HC Wainwright lowered its FY2026 EPS estimate modestly to a loss of $5.44 from $5.39 and trimmed its Q3 2026 estimate to a loss of $1.36 from $1.34. Neurogene is still expected to remain unprofitable, with consensus full-year EPS at a loss of $5.63.
• Negative Sentiment: The company’s latest quarterly results missed analyst expectations, reporting a $1.53-per-share loss versus the $1.42 consensus estimate. Continued losses and the absence of current earnings make the stock highly dependent on clinical and development progress.

Neurogene Stock Up 1.4%

NASDAQ NGNE opened at $36.14 on Friday. Neurogene Inc. has a twelve month low of $15.93 and a twelve month high of $43.66. The company’s 50-day simple moving average is $34.11 and its 200 day simple moving average is $26.90. The stock has a market cap of $723.20 million, a P/E ratio of -7.18 and a beta of 1.70.

Neurogene (NASDAQ:NGNE) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($1.53) earnings per share for the quarter, missing the consensus estimate of ($1.42) by ($0.11). Research analysts anticipate that Neurogene Inc. will post -5.62 earnings per share for the current year.

Wall Street Analyst Weigh In

NGNE has been the topic of a number of recent analyst reports. Guggenheim upped their target price on Neurogene from $69.00 to $81.00 and gave the company a “buy” rating in a research report on Wednesday. Rodman & Renshaw started coverage on Neurogene in a research report on Wednesday, June 3rd. They issued a “buy” rating and a $70.00 target price on the stock. UBS Group set a $70.00 price objective on shares of Neurogene in a report on Wednesday, June 3rd. Canaccord Genuity Group reduced their target price on shares of Neurogene from $180.00 to $166.00 and set a “buy” rating for the company in a report on Wednesday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Neurogene in a research report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $83.67.

Insider Buying and Selling

In other news, CFO Christine Mikail Cvijic sold 4,200 shares of Neurogene stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $36.13, for a total transaction of $151,746.00. Following the transaction, the chief financial officer owned 84,040 shares in the company, valued at $3,036,365.20. The trade was a 4.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 9,600 shares of company stock worth $339,932. Company insiders own 11.68% of the company’s stock.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.